XENE vs RLAY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
XENE · Xenon Pharmaceuticals$39.17 ▲ 3.95%
RLAY · Relay Therapeutics$18.60 ▲ 9.41%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- XENE +2.0%
- RLAY +201.5%
Head to head
| Metric | XENE | RLAY |
|---|---|---|
| Price | $39.17 | $18.60 |
| Change today | ▲ 3.95% | ▲ 9.41% |
| Market cap | $3.79B | $4.11B |
| Return, 3 months | -39.0% | -6.7% |
| Return, year to date | -12.6% | +119.9% |
| Return, 1 year | +2.4% | +207.4% |
| P/E (TTM) | – | – |
| P/B | 3.1 | 5.0 |
| P/E percentile vs own 5y | 98th | 6th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -48.3% |
| Net profit growth (YoY) | -30.7% | -18.9% |
| Gross margin | – | – |
| Operating margin | – | -2,999.4% |
| Net margin | – | -2,763.6% |
| Return on equity | -43.6% | -36.8% |
| Analyst target vs. price | +89.7% | +45.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 53 | 53 |
| 30-day volatility | 37.9% | 62.7% |
| Max drawdown, 1 year | -52.8% | -28.2% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RLAY is the largest of the group by market value.
- RLAY has returned the most over the past year.
- XENE has been the calmest stock over the last 30 days.